Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group’s lead product, Feraccru®/Accrufer® has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer® with Shield currently in the process of selecting a commercialisation partner.
Developed a breakthrough iron deficiency drug
Feraccru, known as Accrufer in the States, recently won approval in the US
Treatment awarded a broad label to treat iron deficiency in adults, significantly widening its potential audience
Shield has tied up an exclusive deal in China with ASK Pharm
One has to kiss a lot of frogs before one finds oneself puckering up to a prince